Liesl Page‐Shipp

The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis

Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch et al. · New England Journal of Medicine · 2009 · 836 citations · Full text

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt et al. · The Lancet · 2015 · 248 citations

Pulmonary Tuberculosis, Phase 2B, Tuberculosis Prevention +9

Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study

Keertan Dheda, Karen Shean, Alimuddin Zumla et al. · The Lancet · 2010 · 248 citations

Pulmonary Tuberculosis, Treatment And Prevention, Tuberculosis Prevention +8

Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis

M. Plit, Ronald Anderson, C.E.J. Van Rensburg et al. · European Respiratory Journal · 1998 · 138 citations · Full text

Pulmonary Tuberculosis, Antibiotics, Spirometric Parameters +15

Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention

Lindsey R. Baden, Etienne Karita, Gaudensia Mutua et al. · Annals of Internal Medicine · 2016 · 84 citations · Full text